MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- AUROBINDO PHARMA - ACTAVIS (US)
AUROBINDO PHARMA vs ACTAVIS (US) - Comparison Results
AUROBINDO PHARMA Change
Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More
ACTAVIS (US)
Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
Financials
 AUROBINDO PHARMA  ACTAVIS |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| AUROBINDO PHARMA Mar-18 |
ACTAVIS Dec-18 |
AUROBINDO PHARMA/ ACTAVIS |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 809 | 13,311 | - | |
| Low | Rs | 504 | 8,929 | - | |
| Sales per share (Unadj.) | Rs | 281.1 | 3,265.1 | - | |
| Earnings per share (Unadj.) | Rs | 41.4 | -1,051.7 | - | |
| Cash flow per share (Unadj.) | Rs | 50.9 | 344.1 | - | |
| Dividends per share (Unadj.) | Rs | 2.50 | 0 | - | |
| Dividend yield (eoy) | % | 0.4 | 0 | - | |
| Book value per share (Unadj.) | Rs | 199.4 | 13,467.2 | - | |
| Shares outstanding (eoy) | m | 585.88 | 332.60 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 2.3 | 3.4 | 68.6% | |
| Avg P/E ratio | x | 15.9 | -10.6 | -150.1% | |
| P/CF ratio (eoy) | x | 12.9 | 32.3 | 39.9% | |
| Price / Book Value ratio | x | 3.3 | 0.8 | 398.8% | |
| Dividend payout | % | 6.0 | 0 | - | |
| Avg Mkt Cap | Rs m | 384,630 | 3,698,480 | 10.4% | |
| No. of employees | `000 | 17.3 | 16.9 | 102.6% | |
| Total wages/salary | Rs m | 21,308 | 0 | - | |
| Avg. sales/employee | Rs Th | 9,500.7 | 64,259.6 | 14.8% | |
| Avg. wages/employee | Rs Th | 1,229.4 | 0 | - | |
| Avg. net profit/employee | Rs Th | 1,397.9 | -20,698.1 | -6.8% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 164,666 | 1,085,988 | 15.2% | |
| Other income | Rs m | 1,020 | 20,768 | 4.9% | |
| Total revenues | Rs m | 165,686 | 1,106,755 | 15.0% | |
| Gross profit | Rs m | 37,718 | 28,458 | 132.5% | |
| Depreciation | Rs m | 5,580 | 464,236 | 1.2% | |
| Interest | Rs m | 777 | 62,668 | 1.2% | |
| Profit before tax | Rs m | 32,380 | -477,678 | -6.8% | |
| Minority Interest | Rs m | 31 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 121,827 | 0.0% | |
| Tax | Rs m | 8,183 | -6,054 | -135.2% | |
| Profit after tax | Rs m | 24,229 | -349,797 | -6.9% | |
| Gross profit margin | % | 22.9 | 2.6 | 874.1% | |
| Effective tax rate | % | 25.3 | 1.3 | 1,994.1% | |
| Net profit margin | % | 14.7 | -32.2 | -45.7% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 121,878 | 445,415 | 27.4% | |
| Current liabilities | Rs m | 86,806 | 394,029 | 22.0% | |
| Net working cap to sales | % | 21.3 | 4.7 | 450.1% | |
| Current ratio | x | 1.4 | 1.1 | 124.2% | |
| Inventory Days | Days | 130 | 20 | 663.1% | |
| Debtors Days | Days | 68 | 66 | 103.1% | |
| Net fixed assets | Rs m | 81,037 | 122,928 | 65.9% | |
| Share capital | Rs m | 586 | 0 | - | |
| Net worth | Rs m | 116,804 | 4,479,192 | 2.6% | |
| Long term debt | Rs m | 4,512 | 1,577,286 | 0.3% | |
| Total assets | Rs m | 211,052 | 7,001,997 | 3.0% | |
| Interest coverage | x | 42.7 | -6.6 | -644.2% | |
| Debt to equity ratio | x | 0 | 0.4 | 11.0% | |
| Sales to assets ratio | x | 0.8 | 0.2 | 503.0% | |
| Return on assets | % | 11.8 | -4.1 | -288.9% | |
| Return on equity | % | 20.7 | -7.8 | -265.6% | |
| Return on capital | % | 27.4 | -4.8 | -565.1% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 19,548 | 387,982 | 5.0% | |
| From Investments | Rs m | -19,570 | 213,146 | -9.2% | |
| From Financial Activity | Rs m | 8,642 | -665,894 | -1.3% | |
| Net Cashflow | Rs m | 8,922 | -64,442 | -13.8% | |
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 68.79 Rs / USD
Compare AUROBINDO PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Compare AUROBINDO PHARMA With: PFIZER JUBILANT LIFE SCIENCES PROCTER & GAMBLE HEALTH NATCO PHARMA STERLING BIOTECH
|
| |
Today's Market
Sensex Ends 560 Points Lower; Auto and Banking Stocks Witness Huge Selling(Closing)
India share markets continued to witness selling pressure during closing hours and ended their day deep in the red.
Related Views On News
AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)
May 30, 2019 | Updated on May 30, 2019For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)
Feb 12, 2019 | Updated on Feb 12, 2019For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Dec 19, 2018 | Updated on Dec 19, 2018Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound (Profit Hunter)
Jul 9, 2019As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.
2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On... (The 5 Minute Wrapup)
Jul 12, 2019Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.
After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors (The 5 Minute Wrapup)
Jul 8, 2019A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...
Here's What to Do with Falling Small Cap Stocks (Profit Hunter)
Jul 10, 2019There are some great buying opportunities in the market right now - and the small cap space is your best bet.
Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock (The 5 Minute Wrapup)
Jul 10, 2019Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.
More|
| |
AUROBINDO PHARMA SHARE PRICE
Jul 19, 2019 03:35 PM
TRACK AUROBINDO PHARMA
- Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON AUROBINDO PHARMA
AUROBINDO PHARMA 5-YR ANALYSIS
COMPARE AUROBINDO PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.